Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 15/20 | 0.39 |
| ▸ | GUCY1B1 | Q02153 | 15/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | CFD | P00746 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10071129 | 0.85 | GUCY1A1 (0.42) | GUCY1A1GUCY1B1CNR1CNR2HTR3A | |
| SCHEMBL13733845 | 0.85 | GUCY1A1 (0.43) | GUCY1A1GUCY1B1CNR1CNR2HTR3A | |
| Hydrochloric Acid SCHEMBL20140172 | 0.84 | GUCY1A1 (0.41) | GUCY1A1GUCY1B1CNR1CNR2HTR3A | |
| SCHEMBL13734557 | 0.80 | GUCY1A1 (0.39) | GUCY1A1GUCY1B1CNR1CNR2HTR3A | |
| Acetic Acid SCHEMBL15065459 | 0.80 | GUCY1A1 (0.46) | GUCY1A1GUCY1B1CNR1CNR2HTR3A | |
| SCHEMBL10070141 | 0.76 | GUCY1A1 (0.40) | GUCY1A1GUCY1B1 | |
| SCHEMBL20161116 | 0.75 | ATM (0.48) | GUCY1A1GUCY1B1ATM | |
| SCHEMBL14777070 | 0.75 | CFD (0.38) | GUCY1A1GUCY1B1CNR1CNR2HTR3A | |
| SCHEMBL20161260 | 0.74 | PDE5A (0.44) | GUCY1A1GUCY1B1 | |
| SCHEMBL18999259 | 0.73 | CNR1 (0.38) | GUCY1A1GUCY1B1CNR1CNR2HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| WO-2018089330-A2 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071318-A1 | SGC STIMULATORS | GUCY1A2, GMPS, PDE2A | GUCY1A1 4/4885GUCY1B1 6/4885CNR1 1432/4885 |
| US-20220017515-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, PDE2A | GUCY1A1 4/4885GUCY1B1 6/4885CNR1 1421/4885 |
| US-11180493-B2 | SGC stimulators | GUCY1A2, GMPS, PDE2A | GUCY1A1 4/4885GUCY1B1 6/4885CNR1 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.